On April 16, 2021,  GEM Listing Committee announced that the IPO registration application of ACROBiosystems was approved. 

On March 28-30, ACROBiosystems participated in 2021 CACLP Expo in Chongqing International Expo Center. There were many highlights in the booth. While ACROBiosystems released new products, it shared R&D experience with the guests, and prepared more than two thousand gifts to interact with the exhibitors. The booth was densely crowded, and visitors and on-site staff communicated adequately.

ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines, and diagnostics. The company employs an application-oriented development strategy, with a particular focus on product design, quality control and solution-based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process.

ACROBiosystems' catalog includes a comprehensive list of disease-associated biomarkers and drug targets from humans to other common species. All of our products are produced with high quality and batch-to-batch consistency to satisfy the rigorous standards of pharmaceutical research and development.

Facing with the pandemic caused by SARS-CoV-2, ACROBiosystems has been keeping a close eye on the development of the epidemic situation and accelerating the development of SARS-COV-2 antigen proteins, antibodies, kits and other related products to facilitate the development of serologic tests, therapeutic antibodies and vaccines.

ACROBiosystems continue to grow and adapt to bring more value to our clients by providing more technical resources and custom services, promoting training and communication opportunities, initiating collaborations in the bio-industry community, and facilitating transactions in the dynamic global and each niche market.